Table 1.
Nivolumab–ipilimumab (n = 10) Median (range) or n (%) |
Nivolumab–ipilimumab plus CBM588 (n = 19) Median (range) or n (%) |
|
---|---|---|
Age (years) | 64 (45–79) | 66 (45–90) |
Gender | ||
Male | 8 (80) | 13 (68) |
Female | 2 (20) | 6 (32) |
Race | ||
White | 9 (90) | 17 (89) |
Asian | 1 (10) | 2 (11) |
Ethnicity | ||
Non-Hispanic or non-Latinx | 6 (60) | 12 (63) |
Hispanic or Latinx | 4 (40) | 7 (37) |
Histologic subtype | ||
Clear cell | 7 (70) | 12 (63) |
Clear cell with sarcomatoid features | 2 (20) | 5 (26) |
Papillary with sarcomatoid features | 1 (10) | 1 (5) |
Sarcomatoid dedifferentiation | – | 1 (5) |
IMDC prognostic risk | ||
Intermediate | 7 (70) | 17 (89) |
Poor | 3 (30) | 2 (11) |
Previous nephrectomy | 4 (40) | 9 (47) |
Number of metastatic sites | ||
≥2 | 10 (100) | 19 (100) |
Most common metastatic sites | ||
Lung | 6 (60) | 13 (68) |
Lymph node | 7 (70) | 8 (42) |
Bone | 4 (40) | 7 (37) |
Soft tissue | 3 (30) | 7 (37) |
Liver | 2 (20) | 3 (16) |
Pancreas | 1 (10) | 3 (16) |
IMDC, International mRCC Database Consortium.